Rigel Pharmaceuticals Inc.
RIGL | NASDAQ
$47.09
+$0.45 (+0.96%)
At close: Sep 21, 2026, 4:00 PM ET
$47.09
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 294.28M | 179.28M | 116.88M | 120.24M | 149.24M | 108.62M |
Cost of Revenue | 19.62M | 18.65M | 7.11M | 1.75M | 1.08M | 895K |
Gross Profit | 274.66M | 160.63M | 109.77M | 118.49M | 148.15M | 107.73M |
Operating Income | 125.47M | 24.19M | -20.49M | -55.55M | -12.5M | -28.97M |
Interest Income | 3.68M | 2.09M | 2.27M | 684K | 47K | 582K |
Pretax Income | 121.83M | 18.37M | -25.09M | -58.57M | -17.31M | -29.74M |
Net Income | 367.02M | 17.49M | -25.09M | -58.57M | -17.91M | -29.74M |
Selling & General & Admin | 115.9M | 113.06M | 105.74M | 112.45M | 91.89M | 76.6M |
Research & Development | 33.3M | 23.38M | 24.52M | 60.27M | 65.24M | 60.1M |
Other Expenses | n/a | n/a | n/a | 1.32M | 3.52M | n/a |
Operating Expenses | 149.2M | 136.44M | 130.26M | 174.04M | 160.65M | 136.7M |
Interest Expense | 7.32M | 7.92M | 6.87M | 3.71M | 4.86M | 1.35M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 168.82M | 155.09M | 137.37M | 175.79M | 161.73M | 137.59M |
Income Tax Expense | -245.2M | 881K | n/a | n/a | 605K | n/a |
Shares Outstanding (Basic) | 17.99M | 17.58M | 17.4M | 17.24M | 17.05M | 16.88M |
Shares Outstanding (Diluted) | 18.84M | 17.69M | 17.4M | 17.24M | 17.05M | 16.88M |
EPS (Basic) | 20.40 | 0.99 | -1.44 | -3.40 | -1.10 | -1.80 |
EPS (Diluted) | 19.48 | 0.99 | -1.44 | -3.40 | -1.10 | -1.80 |
EBITDA | 131.56M | 28.51M | -16.98M | -53.87M | -11.29M | -27.69M |
EBIT | 129.15M | 26.28M | -18.22M | -54.87M | -12.45M | -28.39M |
Depreciation & Amortization | 2.42M | 2.23M | 1.24M | 998K | 1.16M | 706K |
Add to Watchlist
Select watchlists to add or remove RIGL